PredictImmune
Cambridge
About PredictImmune
PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing Inflammatory Bowel Disease (both Crohn’s and ulcerative colitis). Based on world-leading research at Cambridge University, UK, they are developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease. These patients are likely to benefit from early biologics therapy. Physicians, patients and payors all recognise the value of such an approach to the management of Inflammatory Bowel Disease.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $31.4M
- Funding stage: Early Stage Venture
- Last round: Grant (Mar 2023)
- Website: predictimmune.com
- Phone: +44 (0)1223 804 195
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/predictimmune-46472 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.